Mineralys prices $150M common stock offering at $26.50/sh; proceeds to fund royalty repurchase

Mineralys Therapeutics, Inc.

5,660,378 shares at $26.50/share; gross proceeds ~$150M, net ~$142.5M.
Proceeds to partially fund $200M upfront payment to repurchase royalty obligation from Tanabe Pharma.
Offering expected to close June 4, 2026; joint book-runners: BofA, Goldman Sachs, Evercore ISI.
Company separately announced a $500M committed debt facility with Pharmakon Advisors.
Underwriters purchased at $25.3075/share; shelf registration effective on filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.